Pharmacokinetics only
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding Fenofibric acid showed a prolonged half-life at CrCl 30-80 mL/min. Exposure and accumulation were greater in severe impairment. Limits and monitoring Verify the delayed-release capsule's renal starting dose and severe-impairment restriction before use. Follow renal function. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 1, posted Jan 03, 2012 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Oral fidaxomicin requires no adjustment for kidney function. Limits and monitoring Applies to oral therapy for C. difficile infection. Select the age- and formulation-appropriate regimen. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 22, posted Oct 15, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The prescribing information does not call for a renal dose reduction for this inhaled maintenance product. Limits and monitoring Verify the inhaler, active ingredients and indication. The renal guidance does not supply dialysis timing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 15, posted Sep 02, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The prescribing information does not call for a renal dose reduction for this inhaled maintenance product. Limits and monitoring Verify the inhaler, active ingredients and indication. The renal guidance does not supply dialysis timing. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 29, posted Jun 08, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Exercise caution with fluvastatin doses above 40 mg in severe renal impairment because higher doses were not studied there. Limits and monitoring Confirm the immediate-release product and assess muscle symptoms and interacting drugs. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 1, posted Apr 05, 2011 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mild or moderate impairment requires no renal change. Use the XL product cautiously in severe impairment because doses above 40 mg were not studied in that population. Limits and monitoring Watch for muscle symptoms and myopathy. The extended-release tablet has a fixed strength. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 1, posted Aug 05, 2024 | Selected sections checked 2026-11-07. Independent clinical review pending.
Dose or interval change
Renal measure Body-weight-normalized CrCl, mL/min/kg Renal action or finding Select maintenance and induction doses from the indication-specific table using CrCl in mL/min/kg. Measure renal function frequently, adjust when it changes, and provide labeled hydration. Limits and monitoring An absolute CrCl in mL/min cannot be entered directly into this table. Monitor calcium, magnesium, potassium and phosphate. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Dec 12, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
No adjustment within stated limits
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Fostemsavir requires no renal dose reduction, including in patients receiving hemodialysis. Limits and monitoring Use the extended-release tablet instructions and review relevant drug interactions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 9, posted Jun 10, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Pharmacokinetics only
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding In advanced breast cancer trials, fulvestrant concentrations at estimated CrCl values down to 30 mL/min resembled those in patients with normal renal function. Limits and monitoring The observation provides no quantitative guidance below the studied range. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 43, posted Feb 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding The subcutaneous delivery system administers a single fixed 80 mg dose. Markedly reduced renal function may require additional diuretic therapy. Limits and monitoring Assess response to the delivered dose and verify the device. Its fixed dose does not establish equivalence to all IV regimens. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 20, posted Aug 03, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The galcanezumab renal analysis did not include patients with CrCl below 30 mL/min. Limits and monitoring A regimen for severe impairment cannot be derived from these data. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 17, posted Jun 18, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Insufficient evidence
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The effect of severe renal impairment or ESRD on the product's pharmacokinetics is unknown. Limits and monitoring A dialysis dose cannot be derived from the cited data. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 9, posted Jul 02, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
